Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Inventory (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Inventory for 8 consecutive years, with -$150000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 106.67% to -$150000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 45.45% decrease, with the full-year FY2025 number at $6.0 million, down 45.45% from a year prior.
  • Change in Inventory was -$150000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $5.6 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $5.6 million in Q3 2025 to a low of -$474000.0 in Q1 2021.
  • A 5-year average of $1.8 million and a median of $1.8 million in 2023 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: plummeted 218.12% in 2021, then skyrocketed 1782.98% in 2022.
  • Ultragenyx Pharmaceutical's Change in Inventory stood at $990000.0 in 2021, then skyrocketed by 324.75% to $4.2 million in 2022, then plummeted by 51.82% to $2.0 million in 2023, then grew by 11.01% to $2.2 million in 2024, then plummeted by 106.67% to -$150000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Inventory are -$150000.0 (Q4 2025), $5.6 million (Q3 2025), and -$208000.0 (Q2 2025).